CSI Market
Sign In | Register

Kythera Biopharmaceuticals Inc (KYTH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KYTH Annual Cash Flow →
The data below summarizes Kythera Biopharmaceuticals Inc's cash flow activity from Jun 30 2014 to Jun 30 2015, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2015)
6 Months 		(Mar 31 2015) (Dec 31 2014) (Sep 30 2014) (Jun 30 2014)
Operating Activities
Income-65.97
Depreciation & amortization0.37
Amortization of Other Assets0.84
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-4.01
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation11.12
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Amortization Of Preferred Stock Warrant Value-
Revaluation Of Convertible Preferred Stock Warrants-
Increase Decrease In Sublicense Payment-
Increase Decrease In Deferred Development Funds-
Investment Income Amortization Of Premium0.45
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities11.55
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.95
Other Working Capital-0.59
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-47.19
Investing Activities
Capital Expenditures-0.59
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities7.23
Payments to Acquire Marketable Securities-71.22
Real Estate Investments0.00
Proceeds From Maturity Of Marketable Securities41.10
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.50
Other Net-1.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-23.98
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings-6.38
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net134.63
Proceeds From Stock Options And Warrants Exercised6.01
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities134.26
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-47.78
Total Cash Flow63.09
4 historic quarters locked

Sign in to unlock the full Kythera Biopharmaceuticals Inc cash flow history.

Sign In Create Free Account

About KYTH Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.